This month Expert Opinion have delved into the various treatments available for melanoma

Look no further than these (some FREE) articles from Expert Opinion’s April issues!

A list of the ‘Top 15 Drug Launch Superstars’ was recently put together by Fierce Pharma. The Expert Collection has papers covering each of these drugs. The drugs on the list have all been successfully launched and approved and cover a range of indications

Current gene therapy trials for vascular diseases from Halonen et al is our pick of the March issue of Expert Opinion on Biological Therapy from Editor-in-Chief Prof M Morse (Duke, USA)

Laura Runkel and Jennifer Stacey look at the current landscape of therapies in development for Systemic Lupus Erythematous (SLE). Offering commentary on future directions in the area in this timely and well balanced review, you can read their Expert Opinion on Biological Therapy article for free now – available here!

Cardiovascular gene therapy for myocardial infarction by Maria C Scimia, Anna M Gumpert & Walter J Koch is our pick of the Expert Opinion on Biological Therapy February issue from Editor-in-Chief Michael Morse

The Expert Opinion & Expert Reviews journals are now on facebook! Click here to visit our page and ‘LIKE’ us to keep updated of the newest articles and hottest news!

CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road by Saar Gill & David L Porter is our pick of the January issue of Expert Opinion on Biological Therapy from our Editor-in-Chief Professor Michael Morse (Duke, USA)

With annual sales of over US$4 billion, Amgen’s Etancercept is an arthritis blockbuster drug.

In October, Laura Hunt and colleagues from Arthritis UK reviewed the use of Etanercept in the treatment of rheumatoid arthiritis, while in November, Berard and Laxer looked at the use of Etanercept, specifically in treatment of juvenile idiopathic arthritis.

Both papers concluded that the drug is very effective, showing clinical efficacy in 80% of patients with an excellent safety profile.

Five articles from the Expert Opinion Series are within the top 100 most accessed articles from the Informa healthcare journal portfolio in November 2013

In the forthcoming January issue of Expert Opinion on Biological Therapy (EOBT) we take a look at denosumab

Earlier this month, Obinutuzumab, a monoclonal antibody for use in the treatment of CLL became the first drug designated with a “breakthrough” designation to be approved for use by the FDA.

In their drug evaluation article in Expert Opinion on Biological Therapy, Carolyn Owen and Douglas Stewart noted that obinutuzumab was safe and effective and potentially a more potent anti-CD20 therapy than Rituximab. Tim Illidge’s editorial further discussed the expectations and hopes around the therapy.

Biological therapies for psoriasis by Mansouri and colleagues is our Editor’s pick for Expert Opinion on Biological Therapy from Editor-in-Chief Professor Michael Morse (DUke University, USA). Read the article here

In the November issue of EOBT, we hear from Xiao-Qian Wang et al. on their research on the efficacy of HepG2/(ArgI+OTC)4 cells in a micro-bioartificial liver (micro-BAL) device.

Once again at the forefront of new developments, in November Expert Opinion published two reviews on the interesting area of using stem cells to create new cardiac tissue in order to repair damage to the heart.

The Editor’s pick from Professor Michael Morse (Duke University, USA) for the November issue of Expert Opinion on Biological Therapy, is an original reasearch article from Mitchell Jones et al (McGill University, USA) on GI heath status. Read more here…

An article recently published in Expert Opinion on Biological Therapy on emerging targets in mutiple myeloma is the second most downloaded article in September 2013. For more details on this article, read here!

The Editor’s pick from Professor Michael Morse, Duke University (Durham, USA) for the October issue of Expert Opinion on Biological Therapy is “Toward the use of endometrial and menstrual blood mesenchymal stem cells for cell-based therapies” by D Ulrich et al. For more details, read here….

In the last couple of months, antibody mixtures have been a hot topic in Expert Opinion on Biological Therapy with a Drug Evaluation and an Editorial published in the July issue and 2 more Editorials currently available Early Online.

Cell-based therapy for ischemic stroke from Zhang and Chopp is our pick of the September issue of Expert Opinion on Biological Therapy, from our Editor-in-Chief Professor Michael Morse.

The FDA defines a First-in-Class drug as one which uses a new and unique mechanism of action for treating a medical condition. This is a concept that immediately makes you think of words like ‘innovation’, ‘novelty’, ‘potential’, ‘pioneering’ and ‘cutting-edge’ – all things that most pharmaceutical companies look for when considering areas of R&D to pursue and invest in. While they have the potential to boost the company’s pipeline and its profit, First-in-Class drugs also come with much greater risk and are definitely not guaranteed to succeed.

Omalizumab is a new monoclonal therapy which binds to IgE and offers hope for several auto-immune diseases. Expert Opinion on Biological Therapy has recently published several interesting articles on this new therapy, for more information read on…

Camelid single-domain antibody-fragment engineering for (pre)clinical in vivo molecular imaging applications from Jens De Vos, Nick Devoogdt, Tony Lahoutte & Serge Muyldermans is our Editor’s pick of the August issue of EOBT from Editor-in-Chief, Professor Michael Morse.

Rozrolimupab is the first in a new class of antibody therapy and represents the next stage of developement for this key class. Read here for more information.

A review ofRituximab biosimilars from Edward M Vital, Jonathan Kay & Paul Emery is our editor’s pick of the upcoming July issue of Expert Opinion Biological Therapy. Click here to read more!

Increased expression of Human epidermal growth factor receptor 2 (HER2) is very common in breast cancer, occuring in around 20% of cases. Ciara C O’Sullivan & Sandra M Swain discuss the current onoing trials evaluating pertuzumab and the potential of this therapy to become the next first line treatment for breast cancer.

Epigenetics in osteoarthritis and its implication for future therapeutics from Gun-Il Im & You-Jeong Choi is the pick of the May issue from Editor-in-Chief Professor Michael Morse.

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy from Omid Hamid & Richard D Carvajal is our pick of the June issue of Expert Opinion on Biological Therapy from our Editor-in-Chief Professor Michael Morse.

Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma? is an interesting article from Robert Dillman and colleagues published in the May 2013 issue of Expert Opinion on Biological Therapy.

Stem cell therapy for chronic heart failure by Simon Maltais, Steven J Joggerst, Antonis Hatzopoulos, Thomas G DiSalvo, David Zhao, Hak-Joon Sung, Xintong Wang, John G Byrne & Allen J Naftilan is our pick of the April issue of EOBT from Editor-in-Chief Professor Michael Morse.

Several Expert Opinion journals have published articles on miRNAs in the last year with more in the pipeline. This indicates just how important they are in all aspects of research and development and across a variety of therapy areas.

The potential of oncolytic viruses to offer a targeted, highlighly effective cancer treatment has generated interest recently. In this review, E Galanis and colleagues summarise the anti-tumour activity of the replication-competent oncolytic measles virus and discuss clinical data including two compeleted phase I clinical trials.

This article is recommended by the Expert Opinion editorial team as a highlight of our April issue!

The Wall Street Journal recently assessed the current biosimilar R&D pipleine, noting that several of the biggest pharmaceutical companies in the area, Merck, Teva and Samsung, have all experienced significant delays in developing biosimilar versions of current biologic blockbusters. Expert Opinion on Biological Therapy recently published an editorial discussing biosimialr monoclonal antibodies, and some of the challenges involved in developing “generic” versions of these highly complex molecules. Read on to find out more…

This month, Professor Morse our Editor-in-Chief selects a review from Amanda Hooper and John Burnett on Anti-PCSK9 therapies for the treatment of hypercholesterolemia as our Editor’s pick!

Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance by Teresa Troiani, Silvia Zappavigna, Erika Martinelli, Santolo R. Addeo, Paola Stiuso, Fortunato Ciardiello & Michele Caraglia is the pick of our special themed issue on monoclonal antobodies from our Editor-in-Chief, Professor Michael Morse.

This month in our special issue focusing on monoclonal antibodies, Guest Editor Arthur Frankel, from the Texas A&M Health Science Center College of Medicine selects Monoclonal antibodies for the treatment of osteoporosis by E Michael Lewiecki of the New Mexico Clinical Research & Osteoporosis Center as his Editor’s pick.

Expert Opinion on Biological Therapy is happy to present for February a special themed issue focusing on Monoclonal Antibody Therapy.

With Guest Editor Professor Arthur Frankel (Texas A&M), we have invited key leaders in a variety of fields and indications to review the use of monoclonal antibodies and give us their expert opinions on their future potential.

The issue includes reviews on indications ranging from asthma and COPD, osteoporosis and HIV through to a selection of key oncological indications, including lunch cancer, lymophoma and colorectal cancer; as well as a selection of articles looking more closely at one or two specific drugs and an editorial from Paul Declerck on biosimilar monoclonals.

MUC1 immunotherapy is here to stay by Takashi Kimura & Olivera J. Finn is the Editor’s pick of the January issue of Expert Opinion on Biological Therapy, from our Editor-in-Chief, Professor Michael Morse.

Recent advances in the development of new treatments for celiac disease by Marja-Leena Lähdeaho, Katri Lindfors, Laura Airaksinen, Katri Kaukinen & Markku Mäki is our Editor’s pick of the month from Professor Michael Morse at Duke University.

Celiac disease, a debilitating intestinal autoimmune disease, has typically required lifelong avoidance of the offending gluten, which is complicated, expensive, and nutritionally undesirable.

Lahdeaho and colleagues review a range of new therapies in development that modulate the response to the immunogenic gluten and may offer promise for sufferers of this condition.

Showing once again how relevant and interesting the reviews in the Expert Opinion series are, ipilimumab, winner of the best biotechnology product and telaprevir, joint winnder of best pharmaceutical agent, have recently been the subject of review articles.

In May 2012, Expert Opinion on Biological Therapy published a review providing a scientometrtic analysis of emerging trends in regenerative medicine.

The “top” article, which had the strongest citation burst of all papers in regenerative medicine, was by Shinya Yamakana and has recently been awarded the 2012 Nobel Prize for Medicine!

Read more about this in our news story!

RNAi-mediated gene silencing in cancer therapy by Wei-Qiong Yang & Yi Zhang is our Editor’s pick for November 2012.

RNA interference (RNAi)-mediated gene silencing has potential applications across the spectrum of medical diseases; however, its great promise for clinical uses has been limited. Yang and Zhang discuss the potential uses of RNAi for the treatment of cancer and briefly discuss how some limitations may be overcome.

Induced and natural regulatory T cells in human cancer by Theresa L. Whiteside, Patrick Schuler and Bastian Schilling is the Editor’s pick for October 2012

Antibody–drug conjugates – a perfect synergy by John R Adair, Philip W Howard, John A Hartley, David G Williams & Kerry A Chesteris our Editor’s pick of September 2012 issue of EOBT

Improved outlook on HIV-1 prevention and vaccine development by Sandhya Vasan & Nelson L Michael is our Editor’s pick for August 2012.

Recent developments in transposon-mediated gene therapy by Mario Di Matteo, Eyayu Belay, Marinee K Chuah & Thierry VandenDriessche is the Editor’s pick for July 2012.

CNAPS are short strands of nucleic acid, isolated from a range of plasma and serum sources including whole blood, plasma, urine and saliva, which have been found in both healthy people and patients. Some of these sequences have been shown to have a relationship with specific diseases, and this has lead to an interesting new tool for the diagnosis and prognosis of disease.

Whats old is new again! Cytokine-induced killer cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors is our Editor’s pick of the June issue from Professor Michael Morse.

MicroRNA as a novel drug target for cancer therapy is our Editor’s pick from Professor Michael Morse for EOBT in May 2012.

Helping you keep ahead of the curve! New review from EOBT uses CiteSpace software and co-citation analysis to look at new trends in regenerative medicine, our pick for May 2012

In the interests of transparency, the editors would like to take the opportunity to update our readers on our ethical policies, and assure you that we take any breach of said policies very serieously, and will will investigate all such issues as fully as possible.

Nanoparticles disguised as red blood cells to evade the immune system is our Editor’s pick for EOBT in April 2012

Oligonucleotide-directed gene-editing technology: mechanisms and future prospects is our Editor’s choice for March 2012.

Adipose stem cell-based soft tissue regeneration is our Editor’s pick for EOBT in February 2012.

Thymosin Beta-4: a multi-functional regernative peptide, Basic properties and clinical applications is our Editor’s Pick article for EOBT in January 2012.

Dr Sidhu offers an insight into our new ability to generate patient-specific stem cells from somatic cells more easily than ever before and highlights some of the issues which will need to be addressed before this technology can be translated into a therapy. He speculates that the next generation of induced pluripotent stem cells could be produced without genetic manipulation, changing the way we look at personalised medicine and treatment in the future.